Fully human VEGFR2 monoclonal antibody BC001 attenuates tumor angiogenesis and inhibits tumor growth Corrigendum in /10.3892/ijo.2023.5583

Xuan,Zi-Xue; Li,Lin-Na; Zhang,Qi; Xu,Cheng-Wang; Yang,De-Xuan; Yuan,Ye; An,Ying-Hong; Wang,Shan-Shan; Li,Xiao-Wen; Yuan,Shou-Jun

doi:10.3892/ijo.2014.2690

Fully human VEGFR2 monoclonal antibody BC001 attenuates tumor angiogenesis and inhibits tumor growth

Corrigendum in: /10.3892/ijo.2023.5583

Authors:
- Zi-Xue Xuan
- Lin-Na Li
- Qi Zhang
- Cheng-Wang Xu
- De-Xuan Yang
- Ye Yuan
- Ying-Hong An
- Shan-Shan Wang
- Xiao-Wen Li
- Shou-Jun Yuan
View Affiliations

Affiliations: Department of Pharmacology and Toxicology, Beijing Institute of Radiation Medicine, Beijing 100850, P.R. China, Department of Production Technology, Shandong Buchang Shenzhou Pharmaceutical Co., Ltd., Heze 274000, P.R. China
Published online on: October 1, 2014 https://doi.org/10.3892/ijo.2014.2690
Pages: 2411-2420

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The critical role of VEGFR2 in tumor neovascularization and progression has allowed the design of clinically beneficial therapies based on it. Here we show that BC001, a new fully human anti-VEGFR2 monoclonal antibody, inhibits VEGF-stimulated endothelial cell migration, tube formation, and effectively suppressed the transdifferentiation of cancer stem cells into endothelial cells in vitro. Since BC001 exhibited no activity against the mouse VEGFR2 and mouse based study was required to confirm its efficacy in vivo, BC101, the mouse analogue of BC001, was developed. BC101 significantly attenuated angiogenesis according to Matrigel plug assay and resulted in ~80% growth inhibition of mouse B16F10 homograft tumors relative to vehicle control. Similarly, human analogue BC001 suppressed the growth of human xenograft tumors HCT116 and BGC823. Furthermore, immunohistochemical results showed reduced expression of CD31, VEGFR2 and Ki-67, as well as increased expression of Caspase 3 in BC001-treated tumor, which indicated BC001 was able to significantly decrease microvessel density, suppress proliferation and promote apoptosis. These results demonstrate the fully human VEGFR2 monoclonal antibody BC001 can work as an effective inhibitor of tumor angiogenesis and tumor growth both in vitro and in vivo.

View Figures

View References

1	Folkman J: Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 6:273–286. 2007. View Article : Google Scholar : PubMed/NCBI
2	Chung AS, Lee J and Ferrara N: Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer. 10:505–514. 2010. View Article : Google Scholar : PubMed/NCBI
3	Ebos JM and Kerbel RS: Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol. 8:210–221. 2011. View Article : Google Scholar : PubMed/NCBI
4	Wong ML, Prawira A, Kaye AH and Hovens CM: Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas. J Clin Neurosci. 16:1119–1130. 2009. View Article : Google Scholar : PubMed/NCBI
5	Brower V: Tumor angiogenesis - new drugs on the block. Nat Biotechnol. 17:963–968. 1999. View Article : Google Scholar : PubMed/NCBI
6	Olsson AK, Dimberg A, Kreuger J and Claesson-Welsh L: VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 7:359–371. 2006. View Article : Google Scholar : PubMed/NCBI
7	Teicher BA: Antiangiogenic agents and targets: a perspective. Biochem Pharmacol. 81:6–12. 2011. View Article : Google Scholar : PubMed/NCBI
8	Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, et al: Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci USA. 109:2784–2789. 2012. View Article : Google Scholar : PubMed/NCBI
9	Xu HY, Pan YM, Chen ZW, Lin Y, Wang LH, Chen YH, et al: 12-Deoxyphorbol 13-palmitate inhibit VEGF-induced angiogenesis via suppression of VEGFR-2-signaling pathway. J Ethnopharmacol. 146:724–733. 2013. View Article : Google Scholar : PubMed/NCBI
10	Liao X, Zhou X, Mak NK and Leung KN: Tryptanthrin inhibits angiogenesis by targeting the VEGFR2-mediated ERK1/2 signalling pathway. PLoS One. 8:e822942013. View Article : Google Scholar : PubMed/NCBI
11	Holzer TR, Fulford AD, Nedderman DM, Umberger TS, Hozak RR, Joshi A, et al: Tumor cell expression of vascular endothelial growth factor receptor 2 is an adverse prognostic factor in patients with squamous cell carcinoma of the lung. PLoS One. 8:e802922013. View Article : Google Scholar : PubMed/NCBI
12	Lynn KD, Udugamasooriya DG, Roland CL, Castrillon DH, Kodadek TJ and Brekken RA: GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer. BMC Cancer. 10:3972010. View Article : Google Scholar : PubMed/NCBI
13	Soda Y, Marumoto T, Friedmann-Morvinski D, Soda M, Liu F, Michiue H, et al: Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci USA. 108:4274–4280. 2011. View Article : Google Scholar : PubMed/NCBI
14	Hutchinson E: Stem cells: tumour stem cells generate vasculature. Nat Rev Cancer. 11:42011. View Article : Google Scholar : PubMed/NCBI
15	Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, et al: Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature. 468:824–828. 2010. View Article : Google Scholar : PubMed/NCBI
16	Hamerlik P, Lathia JD, Rasmussen R, Wu Q, Bartkova J, Lee M, et al: Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med. 209:507–520. 2012. View Article : Google Scholar : PubMed/NCBI
17	Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, et al: A perivascular niche for brain tumor stem cells. Cancer Cell. 11:69–82. 2007. View Article : Google Scholar : PubMed/NCBI
18	Saraswati S and Agrawal SS: Brucine, an indole alkaloid from Strychnos nux-vomica attenuates VEGF-induced angiogenesis via inhibiting VEGFR2 signaling pathway in vitro and in vivo. Cancer Lett. 332:83–93. 2013. View Article : Google Scholar : PubMed/NCBI
19	Zhang G, Panigrahy D, Mahakian LM, Yang J, Liu JY, Stephen Lee KS, et al: Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. Proc Natl Acad Sci USA. 110:6530–6535. 2013. View Article : Google Scholar : PubMed/NCBI
20	Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, et al: Glioblastoma stem-like cells give rise to tumour endothelium. Nature. 468:829–833. 2010. View Article : Google Scholar : PubMed/NCBI
21	Pang X, Yi T, Yi Z, Cho SG, Qu W, Pinkaew D, et al: Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways. Cancer Res. 69:518–525. 2009. View Article : Google Scholar : PubMed/NCBI
22	Adini A, Fainaru O, Udagawa T, Connor KM, Folkman J and D’Amato RJ: Matrigel cytometry: a novel method for quantifying angiogenesis in vivo. J Immunol Methods. 342:78–81. 2009. View Article : Google Scholar : PubMed/NCBI
23	Gao Z, Zheng J, Yang B, Wang Z, Fan H, Lv Y, et al: Sonodynamic therapy inhibits angiogenesis and tumor growth in a xenograft mouse model. Cancer Lett. 335:93–99. 2013. View Article : Google Scholar : PubMed/NCBI
24	Evellin S, Galvagni F, Zippo A, Neri F, Orlandini M, Incarnato D, et al: FOSL1 controls the assembly of endothelial cells into capillary tubes by direct repression of αv and β3 integrin transcription. Mol Cell Biol. 33:1198–1209. 2013.PubMed/NCBI
25	Scully S, Francescone R, Faibish M, Bentley B, Taylor SL, Oh D, et al: Transdifferentiation of glioblastoma stem-like cells into mural cells drives vasculogenic mimicry in glioblastomas. J Neurosci. 32:12950–12960. 2012. View Article : Google Scholar : PubMed/NCBI
26	Cheng L, Huang Z, Zhou W, Wu Q, Donnola S, Liu JK, et al: Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell. 153:139–152. 2013. View Article : Google Scholar : PubMed/NCBI
27	Dong J, Zhao Y, Huang Q, Fei X, Diao Y, Shen Y, et al: Glioma stem/progenitor cells contribute to neovascularization via transdifferentiation. Stem Cell Rev. 7:141–152. 2011. View Article : Google Scholar : PubMed/NCBI
28	Ribatti D: Cancer stem cells and tumor angiogenesis. Cancer Lett. 321:13–17. 2012. View Article : Google Scholar : PubMed/NCBI
29	Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, et al: Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 66:7843–7848. 2006. View Article : Google Scholar : PubMed/NCBI
30	Chanthery YH, Gustafson WC, Itsara M, Persson A, Hackett CS, Grimmer M, et al: Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma. Sci Transl Med. 4:115ra32012.PubMed/NCBI
31	Carmeliet P and Jain RK: Molecular mechanisms and clinical applications of angiogenesis. Nature. 473:298–307. 2011. View Article : Google Scholar : PubMed/NCBI
32	Potente M, Gerhardt H and Carmeliet P: Basic and therapeutic aspects of angiogenesis. Cell. 146:873–887. 2011. View Article : Google Scholar : PubMed/NCBI
33	Ellis LM and Hicklin DJ: VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 8:579–591. 2008. View Article : Google Scholar : PubMed/NCBI
34	Goel HL and Mercurio AM: VEGF targets the tumour cell. Nat Rev Cancer. 13:871–882. 2013. View Article : Google Scholar : PubMed/NCBI
35	Chatterjee S, Heukamp LC, Siobal M, Schttle J, Wieczorek C, Peifer M, et al: Tumor VEGF: VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J Clin Invest. 123:1732–1740. 2013. View Article : Google Scholar : PubMed/NCBI
36	Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K and Mittal V: Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science. 319:195–198. 2008. View Article : Google Scholar : PubMed/NCBI
37	Huang YH, Yuan JP, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, et al: Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci USA. 109:17561–17566. 2012. View Article : Google Scholar
38	Spring H, Schuler T, Arnold B, Hammerling GJ and Ganss R: Chemokines direct endothelial progenitors into tumor neovessels. Proc Natl Acad Sci USA. 102:18111–18116. 2005. View Article : Google Scholar : PubMed/NCBI
39	Narunsky L, Oren R, Bochner F and Neeman M: Imaging aspects of the tumor stroma with therapeutic implications. Pharmacol Ther. 141:192–208. 2014. View Article : Google Scholar : PubMed/NCBI
40	Tang X: Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer. Cancer Lett. 332:3–10. 2013. View Article : Google Scholar : PubMed/NCBI